Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study

Abstract Introduction Baricitinib, a JAK1/JAK2 inhibitor, is approved for treatment of moderate-to-severe rheumatoid arthritis (RA) in China. This single-arm, prospective, multi-center, post-marketing safety study (PMSS) evaluated the safety and effectiveness of baricitinib in Chinese patients. Meth...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Chan-yuan Wu, Qian Wang, Jian Shi, Xiu-ying Zhang, Rong Du, Jie-ruo Gu, Qi-huan Liu, Jiao Yu, Jia-wei Xu, Yan-jie Zhang, Hao Zhu, Meng-tao Li, Xiao-feng Zeng
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Adis, Springer Healthcare 2023-09-01
Schriftenreihe:	Rheumatology and Therapy
Schlagworte:	Pharmacovigilance Effectiveness Rheumatoid arthritis (RA) Baricitinib Janus kinase (JAK) inhibitor
Online-Zugang:	https://doi.org/10.1007/s40744-023-00596-4
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!